Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23455193,Cmax,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[μg] / [ml],2.35,1013,DB00471,Montelukast
,23455193,Cmax,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[μg] / [ml],2.53,1014,DB00471,Montelukast
,23455193,Cmax,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.53,1015,DB00471,Montelukast
,23455193,AUC0-t,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.28,1016,DB00471,Montelukast
,23455193,AUC0-t,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.67,1017,DB00471,Montelukast
,23455193,AUC0-t,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[μg] / [ml],2.53,1018,DB00471,Montelukast
,23455193,AUC0-t,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.53,1019,DB00471,Montelukast
,23455193,AUC0-t,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.96,1020,DB00471,Montelukast
,23455193,AUC0-inf,"On average, Cmax, AUC0-t, AUC0-inf, was 2.35μg/mL, 1.28µg.h./ml, 1.67µg.h./ml, for innovator drug and 2.53μg/mL, 1.53µg.h./ml, 1.96µg.h./ml, for test drug, respectively.",Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455193/),[h·μg] / [ml],1.96,1021,DB00471,Montelukast
,15497676,absolute recovery,"The absolute recovery was determined to be 94.3% and 98.1% at 15 and 1500 ng ml(-1), respectively.",An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497676/),%,94.3,33633,DB00471,Montelukast
,15497676,absolute recovery,"The absolute recovery was determined to be 94.3% and 98.1% at 15 and 1500 ng ml(-1), respectively.",An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497676/),%,98.1,33634,DB00471,Montelukast
,24424850,flow rate,"The chromatographic resolution was achieved on a Chromolith RP18e column using an isocratic mobile phase consisting of 20 mm ammonium formate-acetonitrile (20:80, v/v) at flow rate of 1.2 mL/min.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),[ml] / [min],1.2,55640,DB00471,Montelukast
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,4,55641,DB00471,Montelukast
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,2.5,55642,DB00471,Montelukast
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,1.2,55643,DB00471,Montelukast
,24563591,LOD,The LOD and LLOQ of present method were found out to be 10 ng mL(-1) and 20 ng mL(-1) respectively.,Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: Application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24563591/),[ng] / [ml],10,56401,DB00471,Montelukast
,24563591,LLOQ,The LOD and LLOQ of present method were found out to be 10 ng mL(-1) and 20 ng mL(-1) respectively.,Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: Application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24563591/),[ng] / [ml],20,56402,DB00471,Montelukast
>,24563591,Extraction recoveries,Extraction recoveries of drug from rabbit plasma were >66.47%.,Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: Application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24563591/),%,66.47,56403,DB00471,Montelukast
,30633968,IC50,Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM).,"Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,2.9,57230,DB00471,Montelukast
,30633968,IC50,"The CYP2C8 IC50 of 4.5 μM in RLM for saroglitazar, supported the use of rats for this DDI study.","Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,4.5,57231,DB00471,Montelukast
,20592724,half-maximal inhibitory concentration (IC(50)),"In human liver microsomes, gemfibrozil 1-O-beta glucuronide inhibited the formation of M6 (but not of M5) from montelukast 35-fold more potently than did gemfibrozil (half-maximal inhibitory concentration (IC(50)) 3.0 and 107 micromol/l, respectively).",Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592724/),[μM] / [l],3.0,67632,DB00471,Montelukast
,20592724,half-maximal inhibitory concentration (IC(50)),"In human liver microsomes, gemfibrozil 1-O-beta glucuronide inhibited the formation of M6 (but not of M5) from montelukast 35-fold more potently than did gemfibrozil (half-maximal inhibitory concentration (IC(50)) 3.0 and 107 micromol/l, respectively).",Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592724/),[μM] / [l],107,67633,DB00471,Montelukast
,29188782,Cmax,The plasma concentration of montelukast was in the range of 1.31-1.76μg/mL at 0.5-12 hours with Cmax value of 1.59±0.16μg/mL at 3.71±0.64 hours.,Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188782/),[μg] / [ml],1.59,86837,DB00471,Montelukast
,29188782,Absorption,"Absorption and elimination half-lives of the montelukast were evaluated as 2.52±0.54 hours and 2.63±0.35 hours, respectively.",Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188782/),h,2.52,86838,DB00471,Montelukast
,29188782,elimination half-lives,"Absorption and elimination half-lives of the montelukast were evaluated as 2.52±0.54 hours and 2.63±0.35 hours, respectively.",Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188782/),h,2.63,86839,DB00471,Montelukast
,29188782,volume of distribution,"The volume of distribution and total body clearance of montelukast were investigated as 0.34±0.01 L/kg and 0.01±0.00 L/hr/kg, respectively.",Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188782/),[l] / [kg],0.34,86840,DB00471,Montelukast
,29188782,total body clearance,"The volume of distribution and total body clearance of montelukast were investigated as 0.34±0.01 L/kg and 0.01±0.00 L/hr/kg, respectively.",Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188782/),[l] / [h·kg],0.01,86841,DB00471,Montelukast
,12520255,systemic clearance (,"The mean systemic clearance (mL/min) values (+/- SD) were not statistically different between the CF subjects (55.53 +/- 44.0 mL/min) and the controls (57.12 +/- 18.42 mL/min), nor were the results significantly different when normalized to body surface area or body weight.",Montelukast pharmacokinetics in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),[ml] / [min],55.53,89386,DB00471,Montelukast
,12520255,systemic clearance (,"The mean systemic clearance (mL/min) values (+/- SD) were not statistically different between the CF subjects (55.53 +/- 44.0 mL/min) and the controls (57.12 +/- 18.42 mL/min), nor were the results significantly different when normalized to body surface area or body weight.",Montelukast pharmacokinetics in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),[ml] / [min],57.12,89387,DB00471,Montelukast
,12520255,elimination half-life,"The mean value for elimination half-life, elimination rate constant, area under the plasma concentration versus time curve, and maximum concentration for controls was 2.37 +/- 0.38 hours, 0.30 +/- 0.05 hours(-1), 2,680.0 +/- 693.6 ng.",Montelukast pharmacokinetics in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),h,2.37,89388,DB00471,Montelukast
,12520255,elimination rate constant,"The mean value for elimination half-life, elimination rate constant, area under the plasma concentration versus time curve, and maximum concentration for controls was 2.37 +/- 0.38 hours, 0.30 +/- 0.05 hours(-1), 2,680.0 +/- 693.6 ng.",Montelukast pharmacokinetics in cystic fibrosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),1/[hours],0.30,89389,DB00471,Montelukast
,12520255,area under the plasma concentration versus time curve,"The mean value for elimination half-life, elimination rate constant, area under the plasma concentration versus time curve, and maximum concentration for controls was 2.37 +/- 0.38 hours, 0.30 +/- 0.05 hours(-1), 2,680.0 +/- 693.6 ng.",Montelukast pharmacokinetics in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),1/[hours],0.30,89390,DB00471,Montelukast
,12520255,maximum concentration,"The mean value for elimination half-life, elimination rate constant, area under the plasma concentration versus time curve, and maximum concentration for controls was 2.37 +/- 0.38 hours, 0.30 +/- 0.05 hours(-1), 2,680.0 +/- 693.6 ng.",Montelukast pharmacokinetics in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520255/),ng,"2,680.0",89391,DB00471,Montelukast
>,18508416,Extraction recoveries,Extraction recoveries of drug from plasma were >48.14%.,A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508416/),%,48.14,90195,DB00471,Montelukast
,24258705,flow rate,"After a simple one step protein precipitation by acetonitrile, zafirlukast and montelukast (IS) were separated on Acquity UPLC BEH(TM) C18 column (50 × 2.1 mm, i.d. 1.7 µm, Waters, USA) using a mobile phase of acetonitrile:water containing 10 mM acetic acid (80:20, v/v) at a flow rate of 0.3 mL/min.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),[ml] / [min],0.3,90989,DB00471,Montelukast
,24258705,total run time,"Zafirlukast and IS were eluted at 0.51 and 1.1 min, respectively with a total run time of only 1.5 min.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),min,1.5,90990,DB00471,Montelukast
,24258705,m/z,"The precursor to product ion transitions of m/z 574.11>462.07 and m/z 584.2>472.1 were used to quantify zafirlukast and IS, respectively.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),,574.11,90991,DB00471,Montelukast
>,24258705,m/z,"The precursor to product ion transitions of m/z 574.11>462.07 and m/z 584.2>472.1 were used to quantify zafirlukast and IS, respectively.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),,462.07,90992,DB00471,Montelukast
>,24258705,m/z,"The precursor to product ion transitions of m/z 574.11>462.07 and m/z 584.2>472.1 were used to quantify zafirlukast and IS, respectively.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),,584.2,90993,DB00471,Montelukast
>,24258705,m/z,"The precursor to product ion transitions of m/z 574.11>462.07 and m/z 584.2>472.1 were used to quantify zafirlukast and IS, respectively.",Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258705/),,472.1,90994,DB00471,Montelukast
,32960980,peak plasma concentrations (Cmax ),"We hypothesized that a 30-mg dose of oral montelukast achieves peak plasma concentrations (Cmax ), comparable to the intravenous preparation (1700 ng/mL) and would be well tolerated in 15 children aged 5 to 12 years with acute asthma exacerbations.",Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960980/),[ng] / [ml],1700,119665,DB00471,Montelukast
,32960980,time to Cmax (tmax ),Median time to Cmax (tmax ) was 3.0 hours.,Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960980/),h,3.0,119666,DB00471,Montelukast
,32960980,Cmax,Six participants (40%) achieved Cmax of 1700 ng/mL or higher.,Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960980/),[ng] / [ml],1700,119667,DB00471,Montelukast
,32960980,Cmax,"However, there was high interindividual variability in peak plasma concentration (median Cmax of 1378 ng/mL; range, 16-4895 ng/mL).",Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960980/),[ng] / [ml],1378,119668,DB00471,Montelukast
,24878424,encapsulation efficiency,MNLCs having a particle size of 181.4 ± 6.5 nm with encapsulation efficiency of 96.13 ± 0.98% were prepared.,Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24878424/),%,96,130917,DB00471,Montelukast
,24215165,lag time,"The results showed that the optimal formulation of PRCs had lag time of 4.5 h, release at 6 and 12 h are 61.95% and 96.29%, respectively.","Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: statistical optimization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215165/),h,4.5,133696,DB00471,Montelukast
,24215165,Tmax,In vivo pharmacokinetic study revealed Tmax of 2 h for marketed tablets; however 7 h for PRCs with initial lag time of 4 h.,"Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: statistical optimization, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215165/),h,2,133697,DB00471,Montelukast
,24215165,Tmax,In vivo pharmacokinetic study revealed Tmax of 2 h for marketed tablets; however 7 h for PRCs with initial lag time of 4 h.,"Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: statistical optimization, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215165/),h,7,133698,DB00471,Montelukast
,24215165,initial lag time,In vivo pharmacokinetic study revealed Tmax of 2 h for marketed tablets; however 7 h for PRCs with initial lag time of 4 h.,"Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: statistical optimization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215165/),h,4,133699,DB00471,Montelukast
,19151602,activation energy,"Permeability of montelukast has an activation energy of 13.7+/-0.7 kcal/mol, consistent with carrier-mediated transport.",Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151602/),[kcal] / [mol],13.7,138498,DB00471,Montelukast
,19151602,maximal inhibition,"Permeability is subject to competition by sulfobromophthalein, estrone-3-sulfate, pravastatin, taurocholic acid, and cholic acid (P<0.05, percentage of control: 72+/-7-86+/-7) and is inhibited by 5-10% citrus juice (P<0.05, maximal inhibition percentage of control: 31+/-2).",Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151602/),,31,138499,DB00471,Montelukast
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB00471,Montelukast
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB00471,Montelukast
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB00471,Montelukast
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB00471,Montelukast
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB00471,Montelukast
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB00471,Montelukast
,15541426,Ki,"CR3465 (L-Tyrosine, N-[(2-quinolinyl)carbonyl]-O-(7-fluoro-2-quinolinylmethyl) sodium salt) is a potent antagonist of [3H]leukotriene D4 ([3H]LTD4) binding to guinea pig lung preparations, its Ki (4.7+/-0.7 nM) being comparable with that of montelukast (5.6+/-0.6 nM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),nM,4.7,145628,DB00471,Montelukast
,15541426,Ki,"CR3465 (L-Tyrosine, N-[(2-quinolinyl)carbonyl]-O-(7-fluoro-2-quinolinylmethyl) sodium salt) is a potent antagonist of [3H]leukotriene D4 ([3H]LTD4) binding to guinea pig lung preparations, its Ki (4.7+/-0.7 nM) being comparable with that of montelukast (5.6+/-0.6 nM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),nM,5.6,145629,DB00471,Montelukast
,15541426,ED50,"Intravenous (i.v.) administration of the agent both antagonized (ED50, 9.9+/-1.9 microg/kg) and reverted LTD4 -induced bronchoconstriction of anesthetized guinea pigs.","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),[μg] / [kg],9.9,145630,DB00471,Montelukast
,15541426,IC50,"CR3465 reduced inflammatory infiltrates in the bronchoalveolar lavage fluid after antigen challenge of sensitized animals, and proved also active in inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) activities exhibited by human platelets and neutrophils (IC50, 2.01+/-0.07 and 4.7+/-0.5 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,2.01,145631,DB00471,Montelukast
,15541426,IC50,"CR3465 reduced inflammatory infiltrates in the bronchoalveolar lavage fluid after antigen challenge of sensitized animals, and proved also active in inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) activities exhibited by human platelets and neutrophils (IC50, 2.01+/-0.07 and 4.7+/-0.5 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,4.7,145632,DB00471,Montelukast
,15541426,IC50,"In line with properties shown by phosphodiesterase inhibitors, CR3465 reduced the contractile response of guinea pig airways to histamine and decreased N-formyl-Met-Leu-Phe (fMLP)-induced degranulation of human neutrophils (IC50, 13.8 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,13.8,145633,DB00471,Montelukast
,15541426,bioavailability,Pharmacokinetic data in the rat demonstrated approximately 100% bioavailability of the agent.,"Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),%,100,145634,DB00471,Montelukast
,20974993,AUC(0→∞),"However when the data were stratified by genotype at c.935 (G/G n = 21, A/G n = 5), a significant reduction in AUC(0→∞) was detected with orange juice in G/G homozygotes (AUC(0→∞), G/G, Gatorade = 2560 ± 900 ng·h·mL(-1) vs AUC(0→∞), G/G, orange juice = 2010 ± 650 ng·h·mL(-1), P = .032).",Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974993/),[h·ng] / [ml],2560,145899,DB00471,Montelukast
,20974993,AUC(0→∞),"However when the data were stratified by genotype at c.935 (G/G n = 21, A/G n = 5), a significant reduction in AUC(0→∞) was detected with orange juice in G/G homozygotes (AUC(0→∞), G/G, Gatorade = 2560 ± 900 ng·h·mL(-1) vs AUC(0→∞), G/G, orange juice = 2010 ± 650 ng·h·mL(-1), P = .032).",Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974993/),[h·ng] / [ml],2010,145900,DB00471,Montelukast
,20974993,AUC(0→∞),"Significantly, A/G heterozygotes showed reduced AUC(0→∞) relative to G/G homozygotes, independent of treatment (AUC(0→∞), G/G, combined treatments = 2310 ± 820 ng·h·mL(-1) vs AUC(0→∞), A/G, combined treatments = 1460 ± 340 ng·h·mL(-1), P = 2.0 × 10(-5)) replicating previous observations.",Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974993/),[h·ng] / [ml],2310,145901,DB00471,Montelukast
,20974993,AUC(0→∞),"Significantly, A/G heterozygotes showed reduced AUC(0→∞) relative to G/G homozygotes, independent of treatment (AUC(0→∞), G/G, combined treatments = 2310 ± 820 ng·h·mL(-1) vs AUC(0→∞), A/G, combined treatments = 1460 ± 340 ng·h·mL(-1), P = 2.0 × 10(-5)) replicating previous observations.",Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974993/),[h·ng] / [ml],1460,145902,DB00471,Montelukast
,24113234,flow rate,"Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase of 0.02M potassium dihydrogen phosphate:methanol (10:90, v/v) pumped at flow rate of 2.0mL/min.",High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24113234/),[ml] / [min],2.0,150387,DB00471,Montelukast
,32787770,lag time,"The drug release from the commercial tablet was immediate and rapid, but capsule has shown an initial 3.5 hr lag time followed by sustained action up to 8 hr.",Therapeutic Potential of Antileukotriene Drug-Camellia sinensis Extract Co-Formulation on Histamine Induced Asthma in Guinea Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787770/),h,3.5,150764,DB00471,Montelukast
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00471,Montelukast
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00471,Montelukast
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00471,Montelukast
,8527292,tmax,"In the evaluated dose range of MK-0476 (20 to 800 mg) the median value of tmax ranged from 2 to 4 h, while the apparent t1/2 value averaged 4 to 5 h.","Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527292/),h,2 to 4,155477,DB00471,Montelukast
,8527292,apparent t1/2,"In the evaluated dose range of MK-0476 (20 to 800 mg) the median value of tmax ranged from 2 to 4 h, while the apparent t1/2 value averaged 4 to 5 h.","Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527292/),h,4 to 5,155478,DB00471,Montelukast
,9429741,trough plasma concentrations,"On average, trough plasma concentrations of montelukast were nearly constant, ranging from 18 to 24 ng mL-1 on days 3-7, indicating that the steady state of montelukast was attained on day 2.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),[ng] / [ml],18 to 24,175726,DB00471,Montelukast
,9429741,accumulation ratio,"The mean accumulation ratio was 1.14, indicating that this dose regimen results in a 14% accumulation of montelukast.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),,1.14,175727,DB00471,Montelukast
,9429741,plasma clearance (Cl),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),[ml] / [min],30.8,175728,DB00471,Montelukast
,9429741,steady-state volume of distribution (Vss),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),l,9.7,175729,DB00471,Montelukast
,9429741,steady-state volume of distribution (Vss),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),h,6.7,175730,DB00471,Montelukast
,9429741,plasma terminal half-life (t1/2),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),l,9.7,175731,DB00471,Montelukast
,9429741,plasma terminal half-life (t1/2),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),h,6.7,175732,DB00471,Montelukast
,9429741,mean residence time in the body (MRTIV),"In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5.4 h, respectively.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),h,5.4,175733,DB00471,Montelukast
,9429741,bioavailability,"Following a 10 mg oral dose, the bioavailability of montelukast in healthy elderly averaged 61%, very close to that (62%) determined previously in healthy young subjects.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),%,61,175734,DB00471,Montelukast
,9429741,bioavailability,"Following a 10 mg oral dose, the bioavailability of montelukast in healthy elderly averaged 61%, very close to that (62%) determined previously in healthy young subjects.",Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429741/),%,62,175735,DB00471,Montelukast
,16707408,AUC(pop),Montelukast 4-mg oral granules in children 3 to 6 months of age yielded systemic exposure (AUC(pop) = 3644.3 +/- 481.5 ng x h/mL) similar to that observed in children aged 6 to 24 months (3226.6 +/- 250.0 ng x h/mL).,Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707408/),[h·ng] / [ml],3644.3,188222,DB00471,Montelukast
,16707408,AUC(pop),Montelukast 4-mg oral granules in children 3 to 6 months of age yielded systemic exposure (AUC(pop) = 3644.3 +/- 481.5 ng x h/mL) similar to that observed in children aged 6 to 24 months (3226.6 +/- 250.0 ng x h/mL).,Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707408/),[h·ng] / [ml],3226.6,188223,DB00471,Montelukast
,22407900,AUC0-24 h,"The AUC0-24 h was 1 835 ng·h/mL for the test formulation, and 1 930 ng·h/mL for the reference formulation.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[h·ng] / [ml],1 835,199706,DB00471,Montelukast
,22407900,AUC0-24 h,"The AUC0-24 h was 1 835 ng·h/mL for the test formulation, and 1 930 ng·h/mL for the reference formulation.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[h·ng] / [ml],1 930,199707,DB00471,Montelukast
,22407900,AUC0-∞,The respective values of AUC0-∞ were 1 917 and 2 015 ng·h/mL.,"Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[h·ng] / [ml],1 917,199708,DB00471,Montelukast
,22407900,AUC0-∞,The respective values of AUC0-∞ were 1 917 and 2 015 ng·h/mL.,"Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[h·ng] / [ml],2 015,199709,DB00471,Montelukast
,22407900,Cmax,"The Cmax of the test and reference products (247 and 283 ng/mL, respectively) reached at 2.25 and 2.72 h, respectively.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[ng] / [ml],247,199710,DB00471,Montelukast
,22407900,Cmax,"The Cmax of the test and reference products (247 and 283 ng/mL, respectively) reached at 2.25 and 2.72 h, respectively.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),[ng] / [ml],283,199711,DB00471,Montelukast
,22407900,terminal t1/2,"Then, they gradually decreased with the mean terminal t1/2 of 5.25 and 5.30 h for the test and reference products, respectively.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),h,5.25,199712,DB00471,Montelukast
,22407900,terminal t1/2,"Then, they gradually decreased with the mean terminal t1/2 of 5.25 and 5.30 h for the test and reference products, respectively.","Relative bioavailability of two 5-mg montelukast sodium chewable tablets: a single dose, randomized, open-label, 2-period crossover comparison in healthy korean adult male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407900/),h,5.30,199713,DB00471,Montelukast
,23715188,Tmax,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),h,2.17,204461,DB00471,Montelukast
,23715188,Tmax,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),h,2.28,204462,DB00471,Montelukast
,23715188,Cmax,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[ng] / [ml],607.4,204463,DB00471,Montelukast
,23715188,Cmax,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[ng] / [ml],627.7,204464,DB00471,Montelukast
,23715188,AUC0-t,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[h·ng] / [ml],"3,316",204465,DB00471,Montelukast
,23715188,AUC0-t,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[h·ng] / [ml],"3,545",204466,DB00471,Montelukast
,23715188,AUC0-∞,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[h·ng] / [ml],"3,450",204467,DB00471,Montelukast
,23715188,AUC0-∞,"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),[h·ng] / [ml],"3,722",204468,DB00471,Montelukast
,23715188,Ke (1/h),"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),,0.25,204469,DB00471,Montelukast
,23715188,Ke (1/h),"Results are indicated for the generic and innovator, respectively: Tmax (h) 2.17±0.73, 2.28±0.88; Cmax (ng/mL) 607.4±122.9, 627.7±134.2; AUC0-t (ng*h/ml) 3,316±861, 3,545±1,070; AUC0-∞ (ng*h/ml) 3,450±904, 3,722±1121; Ke (1/h) 0.25±0.05, 0.23±0.04 in the confidence range of 0.99-1.00 for lnCmax and 0.94-1.06 for lnAUC0-∞.",[Bioequivalence study of montelukast 5 mg chewable tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715188/),,0.23,204470,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],3.3,220248,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],3.0,220249,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],3.5,220250,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],3.4,220251,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],2.9,220252,DB00471,Montelukast
,23970434,Oral,"Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA.",Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23970434/),[l] / [h],3.2,220253,DB00471,Montelukast
,19309765,flow rate,"Chromatographic separation was achieved with 10 mM ammonium acetate (pH 6.4): acetonitrile (15:85, v/v) at a flow rate of 0.50 mL/min on a Discovery HS C(18) column with a total run time of 3.5 min.","Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),[ml] / [min],0.50,220939,DB00471,Montelukast
,19309765,total run time,"Chromatographic separation was achieved with 10 mM ammonium acetate (pH 6.4): acetonitrile (15:85, v/v) at a flow rate of 0.50 mL/min on a Discovery HS C(18) column with a total run time of 3.5 min.","Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),min,3.5,220940,DB00471,Montelukast
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,586.10,220941,DB00471,Montelukast
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,422.10,220942,DB00471,Montelukast
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,409.20,220943,DB00471,Montelukast
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,238.30,220944,DB00471,Montelukast
,11402629,AUCpop,The 4 mg CT dose of montelukast was well tolerated and yielded an AUCpop (2721 ng.h/mL) similar to that of the adult AUCpop (2595 ng.h/mL) observed after a 10 mg FCT dose.,Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402629/),[h·ng] / [ml],2721,231620,DB00471,Montelukast
,11402629,AUCpop,The 4 mg CT dose of montelukast was well tolerated and yielded an AUCpop (2721 ng.h/mL) similar to that of the adult AUCpop (2595 ng.h/mL) observed after a 10 mg FCT dose.,Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402629/),[h·ng] / [ml],2595,231621,DB00471,Montelukast
,15608135,K(i),"The mechanism of inhibition was competitive, with K(i) values ranging from 0.0092 to 0.15 microM.",Selective inhibition of human cytochrome P4502C8 by montelukast. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608135/),μM,0.0092 to 0.15,241374,DB00471,Montelukast
,15076638,peak,"In patients with peak duodenal eosinophil counts between 20-29/hpf (n=19), a positive pain assessment response was observed in 84% of patients receiving montelukast compared to 42% receiving placebo (p < 0.01).",Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15076638/),,20-29,243147,DB00471,Montelukast
,15076638,absorption rate constant (Ka),"Pharmacokinetic analysis yielded parameter estimates for absorption rate constant (Ka), apparent volume of distribution (Vd/F) and elimination rate constant (Kel) of 0.42 h, 0.19 L/kg and 0.26 h, respectively.",Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15076638/),h,0.42,243148,DB00471,Montelukast
,15076638,apparent volume of distribution (Vd/F),"Pharmacokinetic analysis yielded parameter estimates for absorption rate constant (Ka), apparent volume of distribution (Vd/F) and elimination rate constant (Kel) of 0.42 h, 0.19 L/kg and 0.26 h, respectively.",Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15076638/),[l] / [kg],0.19,243149,DB00471,Montelukast
,15076638,elimination rate constant (Kel),"Pharmacokinetic analysis yielded parameter estimates for absorption rate constant (Ka), apparent volume of distribution (Vd/F) and elimination rate constant (Kel) of 0.42 h, 0.19 L/kg and 0.26 h, respectively.",Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15076638/),h,0.26,243150,DB00471,Montelukast
,18296556,area under the concentration-time curve,"The population area under the concentration-time curve estimate after a single 4-mg dose of montelukast was 13 195.7 +/- 2309.8 (standard error) ng.hr/mL, 3.6 times higher than historical values in infants 3 to 24 months of age.",Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296556/),[h·ng] / [ml],13 195.7,249224,DB00471,Montelukast
lower,26561521,f1,"F2 and f1 were higher than 50 and lower than 15, respectively in all selected pH media.",Interchangeability and comparative effectiveness between generic and brand montelukast immediate release tablets after a single oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561521/),,15,252677,DB00471,Montelukast
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.31,259420,DB00471,Montelukast
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.62,259421,DB00471,Montelukast
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.71,259422,DB00471,Montelukast
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.83,259423,DB00471,Montelukast
,25078860,encapsulation efficiency (EE),"The particle size and encapsulation efficiency (EE) were 184.6 ± 2.7 nm and >95%, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),%,95,268675,DB00471,Montelukast
,25078860,Mass,"Mass median diameters (MMD) and density for MNLC-DPI were found to be 15.1 ± 1.4 μm and 0.051 ± 0.002 g/cc, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),μm,15.1,268676,DB00471,Montelukast
,25078860,density,"Mass median diameters (MMD) and density for MNLC-DPI were found to be 15.1 ± 1.4 μm and 0.051 ± 0.002 g/cc, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),[g] / [cc],0.051,268677,DB00471,Montelukast
,25078860,aerodynamic diameters,"Mass median aerodynamic diameters (MMAD) of 3.24 ± 0.67 μm with 69.98 ± 1.9% fine particle fraction (FPF) were obtained at 30 L/min flow rate, whereas at 60 L/min MMAD and FPF were found to be 2.83 ± 0.46 μm and 90.22 ± 2.6%, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),μm,3.24,268678,DB00471,Montelukast
,25078860,MMAD,"Mass median aerodynamic diameters (MMAD) of 3.24 ± 0.67 μm with 69.98 ± 1.9% fine particle fraction (FPF) were obtained at 30 L/min flow rate, whereas at 60 L/min MMAD and FPF were found to be 2.83 ± 0.46 μm and 90.22 ± 2.6%, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),μm,2.83,268679,DB00471,Montelukast
,25078860,FPF,"Mass median aerodynamic diameters (MMAD) of 3.24 ± 0.67 μm with 69.98 ± 1.9% fine particle fraction (FPF) were obtained at 30 L/min flow rate, whereas at 60 L/min MMAD and FPF were found to be 2.83 ± 0.46 μm and 90.22 ± 2.6%, respectively.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),,90,268680,DB00471,Montelukast
,25078860,targeting factor,"The pulmonary pharmacokinetic study demonstrated improved bioavailability, longer residence of drug in the lung and targeting factor of 11.76 for MNLC as compared to montelukast-aqueous solution.",Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078860/),,11,268681,DB00471,Montelukast
,8692739,plasma clearance (CL),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),[ml] / [min],45.5,273852,DB00471,Montelukast
,8692739,steady-state volume of distribution (Vss),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),1,10.5,273853,DB00471,Montelukast
,8692739,steady-state volume of distribution (Vss),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,5.1,273854,DB00471,Montelukast
,8692739,plasma terminal half-life (t1/12),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),1,10.5,273855,DB00471,Montelukast
,8692739,plasma terminal half-life (t1/12),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,5.1,273856,DB00471,Montelukast
,8692739,mean residence time in the body (MRTi.v.),"The mean values of plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/12), and mean residence time in the body (MRTi.v.) of montelukast sodium were 45.5 ml/min, 10.5 1, 5.1 hr, and 3.9 hr, respectively, and remained essentially constant over the i.v. dosage range.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,3.9,273857,DB00471,Montelukast
,8692739,AUC,"Following oral administration of a 10-mg tablet of montelukast sodium, the AUC, maximum plasma concentration (Cmax), time when Cmax occurred (Tmax), apparent t1/12, mean absorption time (MAT), and bioavailability (F) of montelukast sodium averaged 2441 ng.hr/ml, 385 ng/ml.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),[h·ng] / [ml],2441,273858,DB00471,Montelukast
,8692739,CL,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),[ml] / [min],47.6,273859,DB00471,Montelukast
,8692739,Vss,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),1,9.6,273860,DB00471,Montelukast
,8692739,Vss,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,4.5,273861,DB00471,Montelukast
,8692739,t1/2,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),1,9.6,273862,DB00471,Montelukast
,8692739,t1/2,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,4.5,273863,DB00471,Montelukast
,8692739,MRT,"Following i.v. administration of 9 mg of montelukast sodium to females (N = 6), the values of CL, Vss, t1/2, and MRT i.v. averaged 47.6 ml/min, 9.6 1, 4.5 hr, and 3.6 hr, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),h,3.6,273864,DB00471,Montelukast
,8692739,AUC,"Following oral administration of a 10-mg tablet to females, the mean AUC, Cmax, Tmax, apparent t1/2, MAT and F were 2270 ng.hr/ml, 350 ng/ml, 3.3 hr, 4.4 hr, 2.6 hr, and 58%, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),[h·ng] / [ml],2270,273865,DB00471,Montelukast
,8692739,F,"Following oral administration of a 10-mg tablet to females, the mean AUC, Cmax, Tmax, apparent t1/2, MAT and F were 2270 ng.hr/ml, 350 ng/ml, 3.3 hr, 4.4 hr, 2.6 hr, and 58%, respectively.","Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692739/),%,58,273866,DB00471,Montelukast
